Comparative Pharmacology
Head-to-head clinical analysis: LORBRENA versus LYNKUET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LORBRENA versus LYNKUET.
LORBRENA vs LYNKUET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LORBRENA (lorlatinib) is a potent, selective, brain-penetrant inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) tyrosine kinases. It inhibits ALK phosphorylation and downstream signaling pathways (STAT3, PI3K/AKT, MAPK/ERK), and shows activity against most known ALK resistance mutations.
Lynkue (pemigatinib) is a selective, potent, oral inhibitor of fibroblast growth factor receptor (FGFR) 1, 2, and 3. It binds to and inhibits FGFR phosphorylation, leading to reduced tumor cell proliferation and angiogenesis in tumors with FGFR alterations.
100 mg orally once daily with or without food.
28-day cycles: days 1-21, 200 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours (range 20-30 hours), supporting once-daily dosing.
Terminal elimination half-life is approximately 60 hours. This long half-life supports once-daily dosing and allows for steady-state concentrations after ~10-12 days.
Primarily fecal (95%), with unchanged drug accounting for approximately 7% of the dose. Renal excretion is minimal (<1%).
Primarily hepatic metabolism via CYP3A4; biliary/fecal excretion accounts for ~90% of the dose (71% as metabolites, 19% as unchanged drug). Renal elimination is minimal, with <1% excreted unchanged in urine.
Category C
Category C
Kinase inhibitor
Kinase inhibitor